Argus
•
Nov 03, 2026
Merck & Co., Inc.: Pipeline presents opportunity for long-term growth
Summary
Merck & Co. Inc. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Related Reports
Analyst Report: Pfizer Inc.
Analyst Report: Boeing Co/The
Market Digest: AAPL, BA, BSX, EL, DINO, INTC, PWR, NOW, GEV
Nov 03, 2026
•
AAPL, INTC, BSX, DINO, EL, NOW, GEV, PWR, BA
Analyst Report: Chevron Corp
Market Update: NLY, CVX, EPD
Nov 02, 2026
•
CVX, EPD, NLY
Analyst Profile
Jasper Hellweg
Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus’ bespoke research on IPOs.
